BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 30124336)

  • 1. Novel targeted treatment options for advanced cholangiocarcinoma.
    Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
    Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocarcinoma: investigations into pathway-targeted therapies.
    Ntanasis-Stathopoulos I; Tsilimigras DI; Gavriatopoulou M; Schizas D; Pawlik TM
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):765-773. PubMed ID: 32757962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
    Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
    [No Abstract]   [Full Text] [Related]  

  • 4. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical management of cholangiocarcinomas in 2015].
    Marret G; Neuzillet C; Rousseau B; Tournigand C
    Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
    Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 9. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials.
    Bourien H; Lamarca A; McNamara MG; Hubner RA; Valle JW; Edeline J
    Expert Opin Investig Drugs; 2021 Sep; 30(9):975-983. PubMed ID: 34420429
    [No Abstract]   [Full Text] [Related]  

  • 10. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
    Sahin IH; Tan E; Kim R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK; Bridgewater J; Gores GJ; Zhu AX
    J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
    Moeini A; Sia D; Bardeesy N; Mazzaferro V; Llovet JM
    Clin Cancer Res; 2016 Jan; 22(2):291-300. PubMed ID: 26405193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
    Sadeghi S; Bejjani A; Finn RS
    Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
    Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting FGFR inhibition in cholangiocarcinoma.
    Goyal L; Kongpetch S; Crolley VE; Bridgewater J
    Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of ivosidenib for the treatment of
    Tella SH; Mahipal A
    Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.